X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs PIRAMAL ENTERPRISES - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS PIRAMAL ENTERPRISES IPCA LABS/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 29.7 10.9 271.4% View Chart
P/BV x 3.5 1.9 186.9% View Chart
Dividend Yield % 0.1 0.9 15.4%  

Financials

 IPCA LABS   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    IPCA LABS
Mar-18
PIRAMAL ENTERPRISES
Mar-18
IPCA LABS/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs6953,083 22.6%   
Low Rs4001,902 21.0%   
Sales per share (Unadj.) Rs260.2589.7 44.1%  
Earnings per share (Unadj.) Rs19.0284.0 6.7%  
Cash flow per share (Unadj.) Rs33.1310.5 10.6%  
Dividends per share (Unadj.) Rs1.0025.00 4.0%  
Dividend yield (eoy) %0.21.0 18.2%  
Book value per share (Unadj.) Rs213.01,467.0 14.5%  
Shares outstanding (eoy) m126.20180.27 70.0%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x2.14.2 49.8%   
Avg P/E ratio x28.98.8 329.0%  
P/CF ratio (eoy) x16.68.0 206.4%  
Price / Book Value ratio x2.61.7 151.3%  
Dividend payout %5.38.8 59.9%   
Avg Mkt Cap Rs m69,120449,332 15.4%   
No. of employees `00013.36.8 193.7%   
Total wages/salary Rs m7,35919,881 37.0%   
Avg. sales/employee Rs Th2,477.415,535.6 15.9%   
Avg. wages/employee Rs Th555.22,905.4 19.1%   
Avg. net profit/employee Rs Th180.67,482.5 2.4%   
INCOME DATA
Net Sales Rs m32,836106,310 30.9%  
Other income Rs m4182,595 16.1%   
Total revenues Rs m33,254108,906 30.5%   
Gross profit Rs m4,50551,599 8.7%  
Depreciation Rs m1,7774,773 37.2%   
Interest Rs m24029,783 0.8%   
Profit before tax Rs m2,90519,638 14.8%   
Minority Interest Rs m02,801 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m511-28,764 -1.8%   
Profit after tax Rs m2,39451,203 4.7%  
Gross profit margin %13.748.5 28.3%  
Effective tax rate %17.6-146.5 -12.0%   
Net profit margin %7.348.2 15.1%  
BALANCE SHEET DATA
Current assets Rs m19,455118,154 16.5%   
Current liabilities Rs m10,076462,260 2.2%   
Net working cap to sales %28.6-323.7 -8.8%  
Current ratio x1.90.3 755.4%  
Inventory Days Days9827 368.3%  
Debtors Days Days6747 143.9%  
Net fixed assets Rs m20,260113,727 17.8%   
Share capital Rs m252361 70.0%   
"Free" reserves Rs m26,633264,093 10.1%   
Net worth Rs m26,886264,454 10.2%   
Long term debt Rs m2,340242,206 1.0%   
Total assets Rs m41,173726,834 5.7%  
Interest coverage x13.11.7 789.2%   
Debt to equity ratio x0.10.9 9.5%  
Sales to assets ratio x0.80.1 545.2%   
Return on assets %6.411.1 57.4%  
Return on equity %8.919.4 46.0%  
Return on capital %10.810.3 104.4%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,64215,110 103.5%   
Fx outflow Rs m4,8844,298 113.6%   
Net fx Rs m10,75910,813 99.5%   
CASH FLOW
From Operations Rs m3,411-159,666 -2.1%  
From Investments Rs m-1,354-17,677 7.7%  
From Financial Activity Rs m-1,304186,503 -0.7%  
Net Cashflow Rs m7539,364 8.0%  

Share Holding

Indian Promoters % 45.9 52.9 86.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 4.0 285.0%  
FIIs % 25.3 26.6 95.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 16.5 105.5%  
Shareholders   36,892 93,274 39.6%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   ALEMBIC LTD  SUN PHARMA  SANOFI INDIA  FDC LTD.  AJANTA PHARMA  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY19); Net Profit Down 152.5% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 1 bn (down 152.5% YoY). Sales on the other hand came in at Rs 29 bn (up 28.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 19, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS